has the whole industrial chain of R&D, manufacturing, and commercialization. We committed to provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established.
$412.5 million Mabwell Announces Exclusive Licensing Agreement with DISC MEDICINE, INC. for Innovative Drug Candidates of Hematologic Diseases
Mabwell Bioscience Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries
Mabwell Was Ranked in the "List of New and Innovative Chinese Pharmaceutical Forces"
Mabwell Published Pre-clinical Study Results of CD47/PD-L1 Bi-specific Antibody 6MW3211